Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Researchers Have a Nose for How Probiotics Could Affect Hay Fever

Published: Thursday, November 28, 2013
Last Updated: Thursday, November 28, 2013
Bookmark and Share
A study has shown that a daily probiotic drink changed how cells lining the nasal passages of hay fever sufferers reacted to a single out-of-season challenge.

However, it did not lead to significant changes in hay fever symptoms, although this challenge test may not have accurately represented natural allergen exposure.

Our immune system must distinguish between “friends” that can be beneficial to our health and “foes” that can have harmful effects. There is now a growing body of evidence that the gut microbiota, the trillions of bacteria that live in our gut, influences that recognition. When it fails an immune response occurs. This is the case with hay fever, or seasonal allergic rhinitis, when the immune system reacts to pollen or fungal spores.

Previously, a research team at the BBSRC strategically-funded Institute of Food Research (IFR) found that taking a drink containing the probiotic bacterium Lactobacillus casei changed how our immune system responds to grass pollen, measured through changes in molecules produced by the immune system.

A new study, published in the journal PLOS ONE, shows for the first time how these probiotics can interact with cells in our gut to produce systematic changes in cells lining our nasal cavity.

Funded by Yakult and BBSRC, clinicians and scientists at IFR and the University of East Anglia (UEA) on the Norwich Research Park gave 60 hay fever sufferers daily drinks for 16 weeks, outside of the hay fever season. One group was given a drink containing Lactobacillus casei Shirota, and the other group received very similar drinks without the probiotic. The study was double-blinded and placebo controlled, so neither the volunteers nor the scientists knew which group was receiving the probiotic. Samples were taken from the volunteers' nasal cavities and blood, both before and after being challenged with pollen to trigger their allergy. This was then repeated at the end of the 16-week intervention. Clinical measurements of the symptoms of hay fever were also recorded.

Volunteers who received the probiotic drink saw changes in allergic inflammation in their nasal lining, as well as changes in their blood, that are associated with immune responses. This is strong evidence of how the gut microbiota can influence cells of the gut lining, and have a systematic influence on our bodies and distant cells, such as those lining our nasal passages. But despite this, the probiotic had no detectable effect on the symptoms of hay fever.

Hay fever is a complicated condition to assess, and mimic in a clinical setting. The researchers used a single allergy challenge, applied to the volunteers' nasal passage, to provide a standard, reproducible test to help ensure all the subsequent results are comparable. In the real world hay fever is usually triggered by longer term exposure to the allergen, variable in strength and timing over a period of days or weeks. The IFR researchers are now exploring the possibility of carrying out a seasonal study to investigate whether the changes in the nasal mucosa seen in this single challenge study relate to changes in hay fever symptoms triggered by a more realistic natural exposure to pollen.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos